Web of Science

Permanent URI for this collectionhttps://hdl.handle.net/11452/19318

Browse

Browsing by Author ","

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Comparison of protracted infusion 5-fluorouracil and capecitabine in adjuvant chemoradiotherapy for rectal cancer
    (H G E Update Medical Publishing, 2008) ,; Kurt, Meral; Özkan, Lütfi; Kurt, Ender; Çetintaş, Sibel Kahraman; Aygün, Sevilcan; Ercan, İlker; Yılmazlar, Tuncay; Memik, Faruk; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon onkolojisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi onkolojisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0003-1637-910X; 0000-0002-2382-290X; AAA-7047-2020; AAA-3961-2020; 8843050600; 55915679400; 7006207332; 6505881756; 15833990600; 6603789069; 6701800362; 6701813462
    Background/Aims: 5-Fluorouracil-based chemoradiotherapy is the most widely used treatment modality in the adjuvant treatment of rectal cancer. Capecitabine represents a valuable alternative to 5-Fluorouracil in this situation. Methodology: Patients with stage II and stage III rectal adenocarcinoma, who were included in this analysis, received adjuvant chemoradiotherapy consisting of external-beam radiotherapy (50.4-54Gy) either with 5-Fluorouracil at a median dose of 300mg/m(2)/day by protracted venous infusion for 5 days a week, or capecitabine at a median dose of 1650mg/m(2)/day for 5 days a week after surgery. The data concerning the toxicity and the efficacy of the treatments were compared in patients treated with 5-Fluorouracil- and capecitabine-based chemoradiotherapy. Results: Forty-three patients received 5-Fluorouracil, and 24 patients received capecitabine during adjuvant radiotherapy. Although there were no differences between the groups in terms of toxicity rates, distant metastasis-free survival, disease-free survival, and overall survival rates; a trend for improved loco-regional recurrence-free survival rate was observed in the capecitabine arm (p=0.063). Conclusions: Capecitabine is at least as effective as 5-Fluorouracil in the postoperative treatment of rectal adenocarcinoma. Considering the trend for improved loco-regional recurrence-free survival rate in the capecitabine arm, it seems that the drug exerts better synergy with radiotherapy in this situation.